GLP1_NEW
Liraglutide after insulin degludec 0.9 mg injection once daily
LIRAGL_SC_0p9MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -7.44 (-13.08 to -1.81) | 0.91 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.69 (0.21 to 13.19) | 0.48 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.05 (0.00 to 0.51) | 0.97 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.22 (0.00 to 5.75) | 0.84 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.24 (0.00 to 7.25) | 0.80 |